The LiBBY trial — Life's End Benefits of cannaBidiol and tetrahYdrocannabinol — tested a prescription THC-plus-CBD oil for agitation in hospice-eligible advanced dementia. Adult children can ask focused safety questions about infections, deaths, and whether results apply to a parent. Agitation here means severe restlessness, aggression, or distress near end of life. LiBBY studied symptom relief, not memory improvement, in a very frail group.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY actually test?
- How much did agitation change?
- What safety signals need attention?
- What can adult children ask the care team?
- Does this support store cannabis for early memory loss?
What did LiBBY actually test?
According to the Alzheimer's Association, the 12-week Phase 2 trial enrolled 120 hospice-eligible people with advanced dementia and significant agitation the Association announcement. It was multicenter, randomized, double-blind, and placebo-controlled across 10 U.S. sites with home visits.
Pennington Biomedical Research Center reports treated participants received purified oral oil with 2 mg THC plus 100 mg CBD twice daily the Center trial summary. The formula was called T2:C100. The goal was agitation at end of life.
How much did agitation change?
Active treatment reduced agitation by week 2 and held separation through week 12. The Cohen-Mansfield Agitation Inventory difference was large and statistically strong.
Georgetown University School of Medicine reports 83.9% improved at week 2 and 87.2% at week 12 on treatment. Placebo rates were 30.5% and 23.6%. That means nearly 9 in 10 treated participants improved by global rating.
What safety signals need attention?
Overall treatment-emergent events were similar, at 46.7% for THC/CBD versus 42.4% for placebo. Those were mainly infections and gastrointestinal disorders expected in frail hospice patients.
NeurologyLive reports serious adverse events were higher with treatment, at 23.3% versus 11.9% on placebo the trial results coverage. Serious infections were 11.7% versus 1.7%, and deaths were 13.1% versus 5.1%. Investigators judged none of the serious events drug-related, but the small end-of-life sample cannot rule out risk.
What can adult children ask the care team?
Bring the trial printout and your parent's medication, infection, and fall history. Ask how hospice goals shape the tradeoff between calm and medical risk. Clarify who would monitor response and stop treatment.
- Was my parent like the LiBBY patients in frailty, agitation severity, and setting?
- What infection signs should trigger a call during the first two weeks?
- How would sedation, swallowing, falls, or drug interactions be checked?
- When would we continue, lower the dose, or stop?
Does this support store cannabis for early memory loss?
No. LiBBY does not establish safety for dispensary or over-the-counter cannabis for early memory loss.
Dose purity, medical supervision, and patient frailty were very different from home use. The study was funded by the National Institute on Aging and led by academic dementia centers. There is still no FDA-approved drug for agitation in late-stage dementia, so families should discuss trial limits before seeking non-prescription products.
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Questions Adult Children Can Ask About the Research
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: Questions Adult Children Can Ask About the Research
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Questions Adult Children Can Ask About the Research
